{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:00:58Z","timestamp":1790823658707,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":2028,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1111\/ajt.14090","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T10:36:41Z","timestamp":1477305401000},"page":"1358-1369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data"],"prefix":"10.1016","volume":"17","author":[{"given":"Y.","family":"Qazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.L.","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.R.","family":"Peddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Shihab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tomlanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"McCague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mulgaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/ajt.14090_bib1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-6143.2004.00332.x","article-title":"Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era","volume":"4","author":"Meier-Kriesche","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.14090_bib2","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1111\/ajt.12437","article-title":"Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen","volume":"13","author":"Chhabra","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.14090_bib3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1111\/ajt.14090_bib4","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2165\/11319260-000000000-00000","article-title":"Immunosuppressive drugs in kidney transplantation: Impact on patient survival, and incidence of cardiovascular disease, malignancy and infection","volume":"69","author":"Marcen","year":"2009","journal-title":"Drugs"},{"key":"10.1111\/ajt.14090_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/01.TP.0000128636.70499.6E","article-title":"Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology","volume":"78","author":"Nankivell","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/ajt.14090_bib6","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/ajt.14090_bib7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies","volume":"4","author":"Vitko","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.14090_bib8","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/01.TP.0000140486.97461.49","article-title":"Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study","volume":"78","author":"Nashan","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/ajt.14090_bib9","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.14090_bib10","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: A randomized controlled trial","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transplant"},{"issue":"S2","key":"10.1111\/ajt.14090_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ajt.13666","article-title":"OPTN\/SRTR 2014 Annual data report","volume":"16","author":"Hart","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.14090_bib12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/TP.0b013e318166927b","article-title":"Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness","volume":"85","author":"Chan","year":"2008","journal-title":"Transplantation"},{"key":"10.1111\/ajt.14090_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/TP.0b013e3181de1d67","article-title":"Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients","volume":"90","author":"Chan","year":"2010","journal-title":"Transplantation"},{"key":"10.1111\/ajt.14090_bib14","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":"Everolimus plus early tacrolimus minimization: A phase III, randomized, open-label, multicentre trial in renal transplantation","volume":"25","author":"Langer","year":"2012","journal-title":"Transpl Int"},{"key":"10.1111\/ajt.14090_bib15","first-page":"45","article-title":"ICH harmonized tripartite guideline: Guideline for Good Clinical Practice","volume":"47","year":"2001","journal-title":"J Postgrad Med"},{"key":"10.1111\/ajt.14090_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","article-title":"Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey","volume":"41","author":"Coresh","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/ajt.14090_bib17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pst.511","article-title":"Designing a non-inferiority study in kidney transplantation: A case study","volume":"10","author":"Witte","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1111\/ajt.14090_bib18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0197-2456(02)00304-5","article-title":"Assessing treatment efficacy in noninferiority trials","volume":"24","author":"Wang","year":"2003","journal-title":"Control Clin Trials"},{"key":"10.1111\/ajt.14090_bib19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/sim.1400","article-title":"Design and analysis of non-inferiority mortality trials in oncology","volume":"22","author":"Rothmann","year":"2003","journal-title":"Stat Med"},{"issue":"2 Suppl 1","key":"10.1111\/ajt.14090_bib20","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification","volume":"39","author":"Foundation","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/ajt.14090_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/OAJCT.S63058","article-title":"TRANSFORM: A novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation","volume":"6","author":"Pascual","year":"2014","journal-title":"Open Access J Clin Trials"},{"key":"10.1111\/ajt.14090_bib22","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1600-6143.2009.02726.x","article-title":"Calcineurin inhibitor minimization in the Symphony study: Observational results 3 years after transplantation","volume":"9","author":"Ekberg","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.14090_bib23","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1600-6143.2006.01645.x","article-title":"Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study","volume":"7","author":"Ekberg","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.14090_bib24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/tri.12252","article-title":"A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients","volume":"27","author":"Chadban","year":"2014","journal-title":"Transpl Int"},{"issue":"2S","key":"10.1111\/ajt.14090_bib25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/01.tp.0000332215.21482.27","article-title":"Post-operative tissue regeneration in renal transplantation: Comparable outcome with everolimus or MMF [abstract]","volume":"86","author":"Margreiter","year":"2008","journal-title":"Transplantation"},{"key":"10.1111\/ajt.14090_bib26","doi-asserted-by":"crossref","first-page":"E625","DOI":"10.1111\/ctr.12223","article-title":"Wound events in kidney transplant patients receiving de novo everolimus: A pooled analysis of three randomized controlled trials","volume":"27","author":"Cooper","year":"2013","journal-title":"Clin Transplant"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.14090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.14090","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522249867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522249867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ajt.14090\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:18:02Z","timestamp":1761628682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522249867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1600613522249867"],"URL":"https:\/\/doi.org\/10.1111\/ajt.14090","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.14090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}